COMPARATIVE EVALUATION OF ANTIVIRAL DRUGS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS
Keywords:
Chronic viral hepatitis, hepatitis B virus (HBV, hepatitis C virus (HCV),, antiviral drugs, nucleoside/nucleotide analogues (NAs), interferons, direct-acting antivirals (DAAs), viral suppression, resistance profiles, treatment adherenceAbstract
Chronic viral hepatitis, caused primarily by hepatitis B virus (HBV) and hepatitis C virus (HCV), represents a significant global health challenge. The introduction of antiviral drugs has revolutionized treatment strategies, aiming to achieve viral suppression and prevent disease progression. This abstract reviews and compares the effectiveness of current antiviral therapies for HBV and HCV. For HBV, nucleoside/nucleotide analogues (NAs) and interferons are mainstays, with drugs like entecavir and tenofovir disoproxil fumarate (TDF) demonstrating high potency and low resistance rates. In contrast, direct-acting antivirals (DAAs) have transformed HCV treatment, achieving cure rates exceeding 95% with minimal side effects. The comparative evaluation considers factors such as viral suppression, resistance profiles, safety, and treatment adherence. Tailoring therapy to individual patient characteristics remains crucial for optimizing outcomes in chronic viral hepatitis management.
References
Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661-662. doi:10.1002/hep.23190.
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. doi:10.1002/hep.29800.
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398. doi:10.1016/j.jhep.2017.03.021.
Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015;62(1 Suppl) doi:10.1016/j.jhep.2015.02.006.
AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932-954. doi:10.1002/hep.27950.
Ghany MG, Morgan TR. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71(2):686-721. doi:10.1002/hep.30819.
World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Updated April 2015. Accessed July 19, 2024. https://www.who.int/hepatitis/publications/hepatitis-b-guidelines/en/
World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Updated July 2018. Accessed July 19, 2024. https://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2018/en/
